Latest II diabetes Stories
TAIPEI, Taiwan, Sept. 7, 2011 /PRNewswire-Asia/ -- TWi Biotechnology, Inc. announces the successful patient recruitment for the multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb clinical trial of AC-201 for the treatment of Type II Diabetes. A combined 240 patients from 13 US sites plus 8 Taiwan sites have been enrolled to the trial. With six-month treatment and one-month follow-up, completion of the trial data analysis is expected in the early...
(Ivanhoe Newswire) -- Poor maternal diet before conception can result in offspring with reduced birth weights and increased risk of developing type II diabetes and obesity.This work used an animal model to illustrate the importance of maternal diet even before pregnancy begins.During the study mice that were fed a low protein diet for ten weeks before conception (but had a normal diet during pregnancy) gave birth to offspring that had lower birth weights, showed catch-up growth after weaning...
Poor maternal diet before conception can result in offspring with reduced birth weights and increased risk of developing type II diabetes and obesity.This work, which is being presented at the Society for Experimental Biology Annual Conference in Glasgow on Saturday the 2nd of July, used an animal model to illustrate the importance of maternal diet even before pregnancy begins.During the study mice that were fed a low protein diet for ten weeks before conception (but had a normal diet during...
TAIPEI, Taiwan, June 14, 2011 /PRNewswire-Asia/ -- TWi Biotechnology Inc. announced today that the company has enrolled over 50% of the total 240 patients for the Phase IIb clinical trial of AC-201 for the treatment of Type II Diabetes. The randomized, double-blind, placebo-controlled, dose-ranging, multi-center study is primarily designed to evaluate the glycated hemoglglobin A1c (HbA1c) lowering effects of AC-201 in patients with Type II Diabetes Mellitus. Meanwhile, the cardiovascular...
For over ten years certified nutritionist and exercise specialist Isabel De Los Rios has helped dieters understand the long term health and weight loss benefits of eating high quality foods for preventative care against diseases such as Type II Diabetes. Just recently, The American Journal of Clinical Nutrition published a study on Type II Diabetes that supports the theory behind The Diet Solution Program. Florham Park, NJ (PRWEB) June 03, 2011 The Diet Solution Program is a...
BHV Pharmaceuticals, a clinical-stage drug development company, announced today it has entered into a license agreement with Kissei Pharmaceutical Co. Ltd. for exclusive rights to develop and commercialize Remogliflozin Etabonate, a novel, highly selective SGLT2 inhibitor. The agreement provides BHV exclusive global rights excluding Japan, Korea, and Taiwan. Commercialization in China will be shared between Kissei and BHV. Remogliflozin etabonate is a Phase IIb compound in development...
Hyperglycemia during critical illness may be used as a warning of future diabetes. Researchers writing in BioMed Central's open access journal Critical Care have found a significant association between acute illness complicated with hyperglycaemia and the future development of type II diabetes or glucose intolerance.Ivan Gornik worked with a team of researchers from University Hospital Centre Rebro, Croatia, to follow patients for 5 years after they were discharged from the hospital. There...
SAN DIEGO, June 17 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that they have established a worldwide collaboration with Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. The companies will work jointly to identify and advance candidates into pre-clinical development. Boehringer Ingelheim is responsible for the global development and commercialization of...
The research, published online Jan. 31, 2010, in the journal Nature Genetics, presents the first high-resolution atlas of these regulatory elements in the most studied cell type for treatment and prevention of type II diabetes.Together with colleagues in Barcelona, researchers at the University of North Carolina at Chapel Hill have generated a complete map of the areas of the genome that control which genes are "turned on" or "off." The discovery, made in pancreatic islet cells, opens new...
Genes that regulate the energy consumption of cells have a different structure and expression in type II diabetics than they do in healthy people, according to a new study from the Swedish medical university Karolinska Institute published in Cell Metabolism. The researchers believe that these "˜epigenetic mutations' might have a key part to play in the development of the disease.Type II diabetes is characterized by a lower sensitivity to insulin in muscles and organs, and a reduced ability...
